Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Go back to Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy| (NASDAQ: IONS) | Delayed: 56.71 -1.38 (2.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.09 | 52 Week High | $62.68 | |||
| Open | $52.15 | 52 Week Low | $19.59 | |||
| Day High | $57.43 | P/E | N/A | |||
| Day Low | $52.15 | EPS | $0.00 | |||
| Volume | 9,175,678 | |||||
